Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.

This is written in the approval document as:

Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.

Citation

riTUXimab (S/C 1400mg) Maintenance Therapy-56 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6402/600_v2a_riTUXimab_SC_1400mg_Therapy_56_days.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) CD20 + Non-Hodgkin Lymphoma Rituximab
HSE (1) CD20 + Follicular Lymphoma Rituximab